Given the trend of increasing incidence of malignant melanoma, there is a continuing need for improvements in the treatment options. The panel discuss the current standard of care, emphasising the important role of surgery for eligible patients, outline prognostic factors and talk about recent trials investigating therapies such as dacarbazine.